image credit: Pexels

Rentschler Contributes to COVID-19 mRNA Vaccine Manufacture

Rentschler Biopharma agreed to serve as CDMO partner for BioNTech whereby Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase III clinical trial.

Rentschler Biopharma will handle downstream processing to provide purified drug substance. Process and product-related impurities will be removed from the intermediate pool, which has been previously derived from mRNA synthesis.

Read More on Genetic Engineering and Biotechnology News